New York, NY — Bigfoot Biomedical, Inc. today announced it has entered into a development agreement with Dexcom, Inc. to integrate data from the Dexcom Continuous Glucose Monitoring (CGM) System into the Bigfoot insulin delivery system. Bigfoot Biomedical is developing a comprehensive Type 1 Diabetes (T1D) Management System employing simple design, cloud connectivity, and human-centered-automation. The newly announced partnership will enable glucose data to travel seamlessly from the Dexcom transmitter into the Bigfoot system to enable automated delivery of insulin for people with T1D.

“Dexcom’s advanced technologies are a great fit for Bigfoot’s pioneering efforts towards an artificial pancreas,” said Steve Pacelli, EVP, Strategy & Corporate Development at Dexcom. “Bigfoot has made a commitment to automated insulin control based on CGM data, and Dexcom is excited to participate in their development efforts with our sensor technology.”

“We are thrilled to be working with such an innovative, impactful and highly-respected partner,” said Jeffrey Brewer, Chief Executive Officer of Bigfoot.” Bigfoot Biomedical exists to serve the needs of the T1D community, and this partnership is our most important collaboration towards delivering an automated insulin delivery solution for people with T1D.”

Late last week, Bigfoot announced its acquisition of the assets of the Asante Solutions, manufacturer of the Snap insulin pump. With today’s announcement, Bigfoot moves another step closer towards its vision to deliver a fully comprehensive, outcome-based T1D management service for people affected by T1D.

About Bigfoot Biomedical
Bigfoot Biomedical is a health solution company focused on optimizing the care of people with T1D by leveraging data, smart devices and people to deliver improved outcomes valued by patients, providers and payers. Bigfoot has built a prototype automated insulin delivery system, otherwise known as an artificial pancreas, that’s been used in the real-world for over 30,000 hours. Using this automated and connected prototype as its foundational, proof-of-concept inspiration, the Bigfoot vision is to bring to market a scalable, accessible, affordable, integrated solution for the management of T1D – improving life, health, and safety while decreasing healthcare costs.

About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, California, develops and markets continuous glucose monitoring systems for use by people with diabetes, as well as blood glucose monitoring systems used by healthcare providers in hospital critical care settings. For more information on the Dexcom CGM, visit www.dexcom.com.